Does improvement of glycaemic control by nateglinide decrease systolic blood pressure in drug-naive patients with type 2 diabetes?
In drug-naive patients with type 2 diabetes, the improvement in glycaemic control with nateglinide is associated with a decrease in systolic blood pressure.
Our data indicated that LCMR1, strongly overexpressed in NSCLC, might have applications in the clinical diagnosis and treatment of lung cancer.